Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultra-early Atorvastatin in Aneurysmal Subarachnoid Hemorrhage
NCT06559072Phase 3Withdrawn
- Sponsor
- The George Institute for Global Health
- Start
- Sep 2024
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of atorvastatin in aneurysmal subarachnoid hemorrhage (SAH) (2 arms), sponsored by The George Institute for Global Health. Primary endpoint: Utility-Weighted Modified Rankin Scale at 6 months. Planned start Sep 2024; status: withdrawn.
02
Drugs
atorvastatin
03
Conditions
aneurysmal subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on NCT06559072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06559072.